Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Look into the Future of Chronic Pain Management

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief solutions — particularly through its slow-release injection technology. This cutting-edge approach delivers synthetic Cannabidi...
Research | 13 days ago |

Buzz on the Bullboards: TSX stocks to watch after Trump’s win

The past week the TSX and Wall Street saw a significant surge following Donald Trump’s return to the presidency. This political shift is expected to have profound implications for various sectors, particularly the financial and energy industries. Inv...
Jonathon Brown | November 7, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

2024, a breakthrough year for silver

By Chen Lin, chenpicks.com For thousands of years, silver has been a globally recognized commodity. In China, silver was historically used as a standard form of currency, and the term “bank” in Chinese (银行) literally translates to “silver tradi...
Research | June 14, 2024 |

Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is because of high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany’s economic condit...
André Will-Laudien | April 24, 2024 |

Buzz on the Bullboards: Bombardier, Baytex and Tilray turn heads

North American stocks have had a strong week. Markets on both sides of the border responded well to the U.S. Federal Reserve’s vote to hold interest rates between 5.25 per cent and 5.50 per cent for a fifth straight meeting. The central bank has kept r...
Jonathon Brown | March 21, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Buzz on the Bullboards: Who is shining through the market slump?

The market story this week has been less impressive on both sides of the border than what we saw in the week where February turned to March. Recent losses and flatline trading have negated Wall Street’s previous record-setting run where major U.S. indices ...
Jonathon Brown | March 7, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...
Jonathon Brown | January 25, 2024 |
1 2 3 4 5 6 7 8 9 10 ...